New CVS Health research pinpoints tendency toward non-adherence
Booming brand-name drugs contribute to growth
For the U.S. pharmaceutical market, 2015 is already shaping up to be another double-digit growth year in terms of prescription spend, according to IMS Health data. This year’s moving annual total spending has increased 12.7% to $399 billion, as of June.
One of the largest trends that will define this year is the boom in brand-name drugs — particularly specialty drugs and drugs to treat diabetes. Comparing the percent of spending they contributed to growth in 2011 (58%) to the 2015 MAT as of June (90%) underscores the dominance of branded drugs. In the 12 months ended June 2015, there has been a $19.8 billion increase in new-brand spending, and 75% of that is attributed to specialty medications.
Within specialty pharmacy, growth is particularly rapid in hepatitis C treatments. In the second quarter of 2015, hepatitis drugs spurred 3.3% of the total 13.5% growth in spending. Taking the first half of 2015, hepatitis C treatments have seen $9.6 billion in spending growth — a vast majority of which is for new and protected brands. There is a similar trend for diabetes drugs, which have seen $8.6 billion in growth as of June, with new and protected brands constituting almost the entirety of spending growth.
Despite the increase in money going to prescriptions, though, the growth of the total number of prescriptions being filled has been slowing for several years — only growing 0.1% between 2013 and 2014, with another 0.1% growth predicted based on the MAT from June. This has to do with the fact that despite the spending growth surrounding branded drugs, they still only constitute 16.8% of total prescriptions dispensed.
CDC to issue draft guideline on opioid prescribing
WASHINGTON — The Centers for Disease Control and prevention this week announced that a new draft guideline for prescribing opioids to patients with chronic pain was in the works. The move comes in the middle of Pain Awareness month, and amid increases in the amount of opioids prescribed despite a consistency in the amount of pain reported by patients, as well as the 16,000 deaths in 2013 that were caused by opioid overdoses.
“The purpose of the CDC guideline is to provide recommendations for the prescribing of opioid pain medication for patients 18 and older in primary care settings,” the CDC said. “Recommendations focus on the use of opioids in treating chronic pain (i.e., pain lasting longer than 3 months or past the time of normal tissue healing) outside end-of-life care.”
The guideline will include information for providers on how to determine whether a patient needs opioid therapy, which opioids and dosages to use when opioid therapy is needed and risk assessment and monitoring guidance.